To the full analysis
Prestige Consumer Healthcare stock: growth
PBHPrestige Consumer Healthcare reported $1.09B in revenue for fiscal 2026, down 4.3% on the prior year, up 2.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.7%
per year from 2007 to 2026, per share 6.8%
Earnings (Annual rate)
9.1%
per year from 2007 to 2026, per share 9.3%
Free cash flow (Annual rate)
6.7%
per year from 2007 to 2026, per share 6.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 2.9% | 3.0% | 6.7% |
| Revenue per share | 3.6% | 3.9% | 6.8% |
| Earnings | 2.9% | 6.7% | 9.1% |
| Earnings per share | 3.7% | 7.6% | 9.3% |
| Free cash flow | 2.9% | 3.7% | 6.7% |
| Free cash flow per share | 3.7% | 4.6% | 6.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $318.63M | $36.08M | $71.36M |
| 2008 | $326.6M | $33.92M | $44.47M |
| 2009 | $312.72M | −$186.78M | $66.2M |
| 2010 | $302.02M | $32.12M | $58.75M |
| 2011 | $336.51M | $29.22M | $86.02M |
| 2012 | $441.09M | $37.21M | $66.85M |
| 2013 | $623.6M | $65.51M | $127.34M |
| 2014 | $601.88M | $72.62M | $108.82M |
| 2015 | $714.62M | $78.26M | $150.15M |
| 2016 | $806.25M | $99.91M | $170.78M |
| 2017 | $882.06M | $69.4M | $144.8M |
| 2018 | $1.04B | $339.57M | $197.58M |
| 2019 | $975.78M | −$35.8M | $178.8M |
| 2020 | $963.01M | $142.28M | $202.56M |
| 2021 | $943.37M | $164.68M | $213.36M |
| 2022 | $1.09B | $205.38M | $250.28M |
| 2023 | $1.13B | −$82.31M | $221.93M |
| 2024 | $1.13B | $209.34M | $239.38M |
| 2025 | $1.14B | $214.61M | $243.29M |
| 2026 | $1.09B | $190.3M | $246.45M |
Revenue by segment
How Prestige Consumer Healthcare Inc. makes its money and how that has shifted. Names are as the company reports them.
- Gastrointestinal24%
- Women's Health21%
- Eye and Ear Care13%
- Dermatologicals12%
- Analgesics10%
- Cough and Cold9%
- Other11%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal | $101.31M | $152.24M | $160.46M | $172.91M | $161.14M | $204.56M | $226.58M | $231.61M | $255.94M | $259.79M | 23.9% |
| Women's Health | $150.88M | $259.38M | $258.48M | $251.55M | $268.1M | $264.51M | $251.35M | $240.42M | $236.83M | $227.77M | 20.9% |
| Eye and Ear Care | $109.69M | $104.05M | $112.84M | $112.16M | $110.41M | $163.45M | $171.08M | $179.42M | $183.32M | $142.94M | 13.1% |
| Dermatologicals | $87.35M | $96.89M | $97.97M | $103.01M | $107.08M | $120.39M | $123.74M | $129.1M | $128.95M | $125.93M | 11.6% |
| Analgesics | $122.18M | $119.42M | $114.18M | $114.01M | $119.14M | $119.32M | $119.26M | $117.45M | $117.7M | $113.94M | 10.5% |
| Cough and Cold | $108.79M | $111.85M | $103.12M | $111.11M | $70.64M | $107.08M | $126.99M | $119.02M | $106.21M | $101.91M | 9.4% |
| Other | $201.86M | $197.36M | $128.73M | $98.27M | $106.86M | $107.51M | $108.72M | $108.33M | $108.81M | $116.44M | 10.7% |
| Total revenue | $882.06M | $1.04B | $975.78M | $963.01M | $943.37M | $1.09B | $1.13B | $1.13B | $1.14B | $1.09B | 100% |
Revenue by region
Where Prestige Consumer Healthcare Inc. generates its revenue.
- United States78%
- Outside the US22%
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| United States | $837.05M | $812.65M | $799.04M | $910.11M | $953.22M | $886.47M | $897.54M | $850.41M | 78.1% |
| Outside the US | $138.73M | $150.36M | $144.33M | $176.71M | $174.5M | $238.89M | $240.22M | $238.29M | 21.9% |
| Total revenue | $975.78M | $963.01M | $943.37M | $1.09B | $1.13B | $1.13B | $1.14B | $1.09B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Mar 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.